Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 3/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.33 |
| ▸ | CDC25A | P30304 | 1/20 | 0.33 |
| ▸ | CDC25B | P30305 | 1/20 | 0.33 |
| ▸ | CDC25C | P30307 | 1/20 | 0.33 |
| ▸ | THRA | P10827 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19793494 | 1.00 | MAPT (0.40) | MAPTMAOAMAOBELANECA9 | |
| SCHEMBL19793505 | 1.00 | MAPT (0.40) | MAPTMAOAMAOBELANECA9 | |
| SCHEMBL19793500 | 1.00 | MAPT (0.40) | MAPTMAOAMAOBELANECA9 | |
| SCHEMBL19793508 | 1.00 | MAPT (0.40) | MAPTMAOAMAOBELANECA9 | |
| SCHEMBL19793493 | 1.00 | MAPT (0.40) | MAPTMAOAMAOBELANECA9 | |
| SCHEMBL19793512 | 1.00 | MAPT (0.40) | MAPTMAOAMAOBELANECA9 | |
| SCHEMBL19793488 | 0.99 | MAPT (0.38) | MAPTMAOAMAOBELANECA9 | |
| SCHEMBL19793485 | 0.96 | CA9 (0.37) | MAPTMAOAMAOBCA9CDC25A | |
| SCHEMBL19793504 | 0.94 | MAPT (0.37) | MAPTMAOAMAOBCA9S1PR2 | |
| SCHEMBL19793497 | 0.94 | MAPT (0.37) | MAPTMAOAMAOBCA9S1PR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10428273-B2 | Liquid crystal compound having benzopyran skeleton, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2019-10-01 | — | — | US | disclosed |
| US-20180022998-A1 | LIQUID CRYSTAL COMPOUND HAVING BENZOPYRAN SKELETON, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-01-25 | — | — | US | disclosed |
| US-20180022998-A1 | LIQUID CRYSTAL COMPOUND HAVING BENZOPYRAN SKELETON, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428273-B2 | Liquid crystal compound having benzopyran skeleton, liquid crystal composition, and liquid crystal display device | PIEZO1, PYCARD, NLRP1 | MAPT 161/4885MAOA 2782/4885MAOB 3668/4885 |
| US-20180022998-A1 | LIQUID CRYSTAL COMPOUND HAVING BENZOPYRAN SKELETON, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | PIEZO1, NLRP1, PYCARD | MAPT 175/4885MAOA 2771/4885MAOB 3655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.